Opinions on AstraZeneca's stocks have been mixed with a number of factors to consider. Despite recent difficulties such as the China investigation into fraud allegations leading to decrease in their shares, the company has shown considerable strength, demonstrating rising relative strength and with it nearing a key threshold. Investors and analysts are debating whether this is now the right time to buy AstraZeneca. The company is viewed as a top player in the development of Diabetes and Weight Loss medication while also being one of the best global and ADR stocks to buy and a strong growth stock. There are expectations of further upsides to the stock's value due to a boost in cancer therapies, specifically with the purchase of EsoBiotec. Overall, the market consensus appears to be optimistic, with Goldman Sachs notably maintaining a stock target of $98.
AstraZeneca Stocks News Analytics from Tue, 10 Sep 2024 07:00:00 GMT to Sat, 29 Mar 2025 03:45:25 GMT - Rating 6 - Innovation 4 - Information 8 - Rumor -2
